External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
152 patients were screened and 151 patients were enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This study provides an Asian validation of the Meet-URO score, supporting its prognostic utility in this Japanese multicenter cohort receiving first-line ICI-based combinations. Treatment imbalance across Meet-URO groups and a short follow-up warrant cautious interpretation and further validation.
OpenAlex 토픽 ·
Renal cell carcinoma treatment
Cancer Immunotherapy and Biomarkers
Inflammatory Biomarkers in Disease Prognosis
[PURPOSE] The Meet-URO score, incorporating IMDC classification, neutrophil-to-lymphocyte ratio (NLR), and bone metastases, was developed in European patients receiving second-line nivolumab; its appl
- p-value p = 0.0017
- p-value p = 0.0022
- 95% CI 13.2-19.3
- 추적기간 16.1 months
APA
Shugo Yajima, Soichiro Yoshida, et al. (2026). External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.. International urology and nephrology. https://doi.org/10.1007/s11255-026-05153-w
MLA
Shugo Yajima, et al.. "External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.." International urology and nephrology, 2026.
PMID
42012775
Abstract
[PURPOSE] The Meet-URO score, incorporating IMDC classification, neutrophil-to-lymphocyte ratio (NLR), and bone metastases, was developed in European patients receiving second-line nivolumab; its applicability to Asian populations, particularly in real-world first-line immune checkpoint inhibitor (ICI)-based combination cohorts, remains uncertain. We externally validated the Meet-URO score in Japanese patients with metastatic renal cell carcinoma (mRCC) receiving first-line ICI-based combinations.
[METHODS] This retrospective multicenter study enrolled mRCC patients treated with first-line ICI-based combinations at five Japanese institutions, stratified into five Meet-URO groups; overall survival (OS) was the primary endpoint, evaluated using Harrell's C-index.
[RESULTS] Between 2018 and 2022, 152 patients were screened and 151 patients were enrolled. Treatment regimens included nivolumab plus ipilimumab (64.9%), pembrolizumab plus axitinib (27.8%), avelumab plus axitinib (4.0%), and nivolumab plus cabozantinib (3.3%). The median potential follow-up was 16.1 months (95%CI 13.2-19.3), estimated by the reverse Kaplan-Meier method. The Meet-URO score significantly stratified OS (p = 0.0017), cancer-specific survival (p = 0.0022), and progression-free survival (p = 0.0428). The 24-month OS rates were 100%, 94.8%, 55.0%, 54.9%, and 39.7% for Groups 1-5, respectively. The C-index for OS was 0.731 (95%CI 0.655-0.807), numerically higher than but not statistically significantly different from IMDC classification (0.702; bootstrap difference 0.029, 95%CI - 0.082 to 0.134, p = 0.298). Overall response rate and disease control rate differed significantly across groups, whereas grade ≥ 3 adverse events did not.
[CONCLUSION] This study provides an Asian validation of the Meet-URO score, supporting its prognostic utility in this Japanese multicenter cohort receiving first-line ICI-based combinations. Treatment imbalance across Meet-URO groups and a short follow-up warrant cautious interpretation and further validation.
[METHODS] This retrospective multicenter study enrolled mRCC patients treated with first-line ICI-based combinations at five Japanese institutions, stratified into five Meet-URO groups; overall survival (OS) was the primary endpoint, evaluated using Harrell's C-index.
[RESULTS] Between 2018 and 2022, 152 patients were screened and 151 patients were enrolled. Treatment regimens included nivolumab plus ipilimumab (64.9%), pembrolizumab plus axitinib (27.8%), avelumab plus axitinib (4.0%), and nivolumab plus cabozantinib (3.3%). The median potential follow-up was 16.1 months (95%CI 13.2-19.3), estimated by the reverse Kaplan-Meier method. The Meet-URO score significantly stratified OS (p = 0.0017), cancer-specific survival (p = 0.0022), and progression-free survival (p = 0.0428). The 24-month OS rates were 100%, 94.8%, 55.0%, 54.9%, and 39.7% for Groups 1-5, respectively. The C-index for OS was 0.731 (95%CI 0.655-0.807), numerically higher than but not statistically significantly different from IMDC classification (0.702; bootstrap difference 0.029, 95%CI - 0.082 to 0.134, p = 0.298). Overall response rate and disease control rate differed significantly across groups, whereas grade ≥ 3 adverse events did not.
[CONCLUSION] This study provides an Asian validation of the Meet-URO score, supporting its prognostic utility in this Japanese multicenter cohort receiving first-line ICI-based combinations. Treatment imbalance across Meet-URO groups and a short follow-up warrant cautious interpretation and further validation.
같은 제1저자의 인용 많은 논문 (4)
- Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis.
- Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
- Application of serum anti-ENO1 and anti-SSNA1 antibody biomarkers in predicting the prognosis of gastric cancer.
- Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis.